Frontiers in Ophthalmology

Frontiers in Ophthalmology is a gold open access journal from Frontiers Media in Lausanne, launched in 2021 and issued continuously in one volume a year with no issue numbers. It publishes clinical and laboratory work on the eye, from the cornea to the optic nerve, and its 2025 Journal Impact Factor is 2.4, which places it in the second quartile of ophthalmology.《眼科前沿》是 Frontiers Media 在洛桑出版的金色开放获取期刊，2021 年创刊，按年一卷连续出版，不设固定期号。刊物收载从角膜到视神经的眼科临床与实验室研究，2025 年期刊影响因子为 2.4，在眼科学类目位列第二象限。

Scope

• The stated aim is to advance knowledge and understanding of eye diseases and disorders along with their diagnosis and management, and the journal calls itself multidisciplinary rather than tied to a single subspecialty.宗旨写明要推进对眼病与眼部疾患及其诊断和管理的认识，刊物自述为多学科刊物，并不系于单一亚专科。

• Cornea and ocular surface disease is one of the named areas, taking in dry eye, keratoconus, corneal infection and the grafting and refractive surgery that follow them.角膜与眼表疾病是自述领域之一，涵盖干眼、圆锥角膜、角膜感染以及其后的移植与屈光手术。

• Disease mechanisms and etiology form a subject in their own right, so bench work on how ocular tissue fails appears beside clinical description.疾病机制与病因自成一体，眼组织如何失效的实验室研究与临床描述并列刊出。

• Glaucoma is listed, covering intraocular pressure, damage to the optic nerve and the long-term care of a condition that seldom resolves on its own.青光眼在列，涉及眼压、视神经损害，以及这一少有自行缓解可能的疾病的长期照护。

• Neuro-ophthalmology brings in the visual pathway, the pupil and eye movement, ground where ophthalmology and neurology share patients.神经眼科纳入视觉通路、瞳孔与眼球运动，这是眼科与神经病学共同面对患者的地带。

• Ocular inflammation is named on its own, which draws uveitis, scleritis and the immune mechanisms behind them into the remit.眼部炎症被单独点名，葡萄膜炎、巩膜炎及其背后的免疫机制因此落入收稿范围。

• Ophthalmic surgery covers technique, outcome and complication across cataract, vitreoretinal, glaucoma and corneal operations.眼科手术涵盖白内障、玻璃体视网膜、青光眼与角膜手术的技术、结局和并发症。

• Pediatric ophthalmology and strabismus hold a section, from congenital cataract and amblyopia to ocular alignment in childhood.小儿眼科与斜视自成一个分区，从先天性白内障、弱视到儿童期的眼位问题都在其中。

• Randomized clinical trials count as a submission category and are listed among the core interests of the journal instead of being an occasional addition.随机临床试验是可投的稿件类别，被列入刊物的核心关注，并未当作偶一为之的补充。

• Real-world clinical studies sit beside the trials, an acknowledgement that much of ophthalmic practice rests on registry and cohort evidence.真实世界临床研究与随机试验并列，眼科实践中的大量证据本就来自登记库与队列研究。

• Retinal disease runs from diabetic retinopathy and age-related macular degeneration to inherited dystrophies and detachment.视网膜疾病从糖尿病视网膜病变、年龄相关性黄斑变性，延伸到遗传性营养不良与视网膜脱离。

• Therapeutic targets round off the list, taking in drug, gene and cell approaches at the point where a molecular candidate meets a clinical need.治疗靶点收束这份清单，涵盖药物、基因与细胞途径，落在分子候选与临床需求相接之处。

• Manuscripts that touch the eye only in passing are turned away, and the journal cites non-ophthalmic drug research and general microbiome work with no fundamental link to eye health as examples.仅与眼科沾边的稿件会被退回，刊物举出两类例子，一是非眼科药物研究，二是与眼健康无根本关联的泛微生物组研究。

• Studies computed from public datasets are considered, provided the analysis comes with validation and does not rest on the dataset alone.基于公开数据集的计算研究可以投递，前提是分析附有验证，不能只凭数据本身立足。

• The journal ties its purpose to Sustainable Development Goal 3 on good health and well-being and to the 2.2 billion people living with some degree of vision impairment.刊物把自身定位系于联合国可持续发展目标 3（良好健康与福祉），也系于全球 22 亿存在某种程度视力受损的人。

History

• Volume 1 carries the date 2021, the year the National Library of Medicine records as the start of the title and the year from which PubMed indexes it.第 1 卷标注 2021 年，美国国立医学图书馆以这一年为该刊起始年，PubMed 也自此收录。

• Six volumes had appeared by 2026, one for each year of publication, and no issue numbers divide them because articles go online as soon as they are accepted.到 2026 年已出六卷，每年一卷，卷内不设期号，文章一经接收即上线。

• The electronic number 2674-0826 is the only one registered, since the journal has never carried a print edition.登记的刊号只有电子刊号 2674-0826，该刊始终没有印刷版。

• Frontiers Media S.A. of Lausanne has published it from the first volume, and the National Library of Medicine files the imprint under that Swiss city and abbreviates the title Front Ophthalmol (Lausanne).洛桑的 Frontiers Media S.A. 自首卷起即为出版方，美国国立医学图书馆把出版项归入这座瑞士城市，并以 Front Ophthalmol (Lausanne) 作为缩写。

• Open access was the arrangement from the outset, with articles published under CC BY and copyright left with the authors.开放获取自创刊即为既定安排，论文以 CC BY 许可发表，版权留在作者手中。

• The journal's internal short code is fopht, while Front. Ophthalmol. and FRONT OPHTHALMOL-SWI serve citation styles and the citation index.刊物的内部短代码为「fopht」，Front. Ophthalmol. 与 FRONT OPHTHALMOL-SWI 分别供文后引用与引文索引使用。

• Its 2025 Journal Impact Factor is 2.4, the five-year figure is 2.2, and the title ranks 37th of 98 in ophthalmology, in the second quartile.2025 年期刊影响因子为 2.4，五年影响因子为 2.2，在眼科学 98 份期刊中排第 37 位，居第二象限。

• CiteScore is 2.4, the yearly snapshot records 625 citations and 84 articles, and the cited half-life is 2.2 years, short as befits a young title.CiteScore 为 2.4，年度快照记录总被引 625 次、当年发文 84 篇，被引半衰期 2.2 年，与年轻刊物的身份相称。

• The Emerging Sources Citation Index lists the title, PubMed and PubMed Central carry it from volume 1, and Scopus and DOAJ add further coverage.新兴来源引文索引收录该刊，PubMed 与 PubMed Central 自第 1 卷起载入，Scopus 与 DOAJ 另添一层覆盖。

• Preservation runs through CLOCKSS, and every article is deposited with Crossref, so the digital record does not depend on one platform.长期保存依托 CLOCKSS，每篇文章都向 Crossref 存缴，数字记录因此不系于单一平台。

• The gold open access share is complete, which means no subscription revenue supports the journal and every article is free to read.金色开放获取占比为全部，刊物没有订阅收入支撑，每篇文章均可免费阅读。

• Articles carry the DOI prefix 10.3389 that Frontiers uses across its list, and citations give a volume with an article number rather than a page range.文章带有 Frontiers 全系共用的 DOI 前缀 10.3389，引用时给出卷号与文章编号，不给页码范围。

Editors

• Andrew Lee is Field Chief Editor and works from Houston Methodist Hospital in Houston, with a research record in neuro-ophthalmology.（Andrew Lee）担任领域主编，任职于休斯敦的 Houston Methodist Hospital，研究方向为神经眼科。

• Ten specialty sections divide the field, each with a specialty chief editor, and an author picks one of them when submitting.十个专科分区划分整个领域，每区设一位专科主编，作者投稿时须选定其中之一。

• Winfried Amoaku of the University of Nottingham leads the retina section.诺丁汉大学的（Winfried Amoaku）主持视网膜分区。

• Ludwig M. Heindl of the University Hospital of Cologne heads surgical ophthalmology.科隆大学医院的（Ludwig M. Heindl）主管眼科手术分区。

• Alon Kahana, at Oakland University William Beaumont School of Medicine, takes oculoplastics, orbit and trauma.任职于 Oakland University William Beaumont School of Medicine 的（Alon Kahana）负责眼整形、眼眶与眼外伤。

• Vasudevan Lakshminarayanan of the University of Waterloo handles new technologies in ophthalmology.滑铁卢大学的（Vasudevan Lakshminarayanan）负责眼科新技术。

• Shamira Perera, at the Singapore National Eye Center, leads the glaucoma section.新加坡国家眼科中心的（Shamira Perera）主持青光眼分区。

• Rohit Saxena of the All India Institute of Medical Sciences in New Delhi heads pediatric ophthalmology and strabismus.新德里全印医学科学研究所的（Rohit Saxena）主管小儿眼科与斜视。

• Namrata Sharma, from the Dr. R. P. Centre for Ophthalmic Sciences at the same institute, leads cornea and refractive surgery.角膜与屈光手术由（Namrata Sharma）主持，她来自该研究所的 Dr. R. P. Centre for Ophthalmic Sciences。

• Michael Wormstone of the University of Nottingham Ningbo in China leads the lens and cataract section.宁波诺丁汉大学的（Michael Wormstone）主持晶状体与白内障分区。

• Heping Xu, at the Aier Eye Institute in Changsha, heads inflammatory eye diseases.长沙爱尔眼科研究所的（Heping Xu）主管眼部炎症性疾病。

• Associate editors include Tin A Tun of the Singapore Eye Research Institute, Minhaj Nur Alam of UNC Charlotte, Ritu Arora of the Shroff Eye Center in New Delhi, Steven F Abcouwer of the Kellogg Eye Center, Alfredo Adan of the Hospital Clinic of Barcelona and Aniruddha Agarwal of Cleveland Clinic Abu Dhabi.副编辑包括新加坡眼科研究所的（Tin A Tun）、UNC Charlotte 的（Minhaj Nur Alam）、新德里 Shroff Eye Center 的（Ritu Arora）、Kellogg Eye Center 的（Steven F Abcouwer）、巴塞罗那 Hospital Clinic 的（Alfredo Adan），以及克利夫兰诊所阿布扎比分部的（Aniruddha Agarwal）。

• Community reviewers work inside each section and provide the first reports, which the handling associate editor weighs before a decision is reached.社区审稿人在各分区内工作并提供初审意见，由负责的副编辑权衡后形成决定。

• Review is single anonymized, so a reviewer's name is withheld from the author while the author's identity is visible, and the names of editors and reviewers appear with the published article.评审采用单匿名方式，审稿人姓名不向作者公开，作者身份对审稿人可见，论文发表时编辑与审稿人的姓名一并刊出。

• Acceptance requires that the reviewers and the handling editor agree, a rule that gives the handling editor a share of the decision rather than leaving everything to the reports.接收须审稿人与处理编辑意见一致，处理编辑因此分担决定权，而非仅凭审稿报告定夺。

• Nineteen article types are open, among them Original Research, Review, Mini Review, Brief Research Report, Case Report, Clinical Trial, Study Protocol, Systematic Review, Methods, Perspective, Opinion, Hypothesis and Theory, General Commentary, Editorial, Data Report, Technology and Code, Classification, Correction and FAIR² Data.可投的文章类型共 19 种，包括原创研究、综述、小型综述、简报研究、病例报告、临床试验、研究方案、系统综述、方法、视角、观点、假设与理论、一般评论、社论、数据报告、技术与代码、分类、更正，以及 FAIR² 数据。

• Publication costs are banded by article type, with the lowest band free of charge, and authors from low-income and lower-middle-income countries can apply for a waiver.发表费用按文章类型分档，最低一档不收费，低收入与中低收入国家的作者可以申请减免。